BiotechTube

SHR7280

Phase 1Completed
0 watching 0 views this weekπŸ’€ Quiet
33
Hype Score

Development Stage

βœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hormone Sensitive Prostate Cancer

Conditions

Hormone Sensitive Prostate Cancer

Trial Timeline

Sep 24, 2021 β†’ May 25, 2023

NCT ID
NCT04995042

About SHR7280

SHR7280 is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Hormone Sensitive Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04995042. Target conditions include Hormone Sensitive Prostate Cancer.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT04995042Phase 1Completed

Competing Products

20 competing products in Hormone Sensitive Prostate Cancer

See all competitors
ProductCompanyStageHype Score
SomatropinEli LillyPhase 3
77
Somatropin (recombinant deoxyribonucleic acid [rDNA] origin)Eli LillyPre-clinical
23
Datopotamab Deruxtecan (Dato-DXd) + Steroid Containing MouthwashDaiichi SankyoPhase 1
33
Enzalutamide + Placebo + Androgen deprivation therapy (ADT)Astellas PharmaPhase 3
77
EnzalutamideAstellas PharmaPhase 2
52
Enzalutamide + Placebo (No longer applicable in Open Label study period) + Leuprolide Open LabelAstellas PharmaPhase 3
77
Enzalutamide + PlaceboAstellas PharmaPhase 3
77
YM598Astellas PharmaPhase 2
52
pegylated Somatropin + pegylated Somatropin + Jintropin AQSun PharmaceuticalPhase 2
52
PEG-somatropinSun PharmaceuticalApproved
85
PEG-somatropin + PEG-somatropinSun PharmaceuticalApproved
85
PEG-somatropinSun PharmaceuticalPhase 3
77
ONO-4578 + letrozole + Palbociclib + abemaciclibOno PharmaceuticalPhase 1
33
Somatropin + SomatropinEli LillyPhase 3
77
Abemaciclib + Trastuzumab + Fulvestrant + Standard of Care Single Agent ChemotherapyEli LillyPhase 2
52
Somatropin + SomatropinEli LillyPhase 3
77
Abemaciclib + Aromatase Inhibitor + Abemaciclib + FulvestrantEli LillyApproved
85
dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets + placebo; abiraterone acetate tablets; prednisone tabletsJiangsu Hengrui MedicinePhase 1
33
SHR6390 + placeboJiangsu Hengrui MedicinePhase 3
77
SHR7280 tablets + SHR7280 dry suspensionJiangsu Hengrui MedicinePhase 1
33

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85